Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.38 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8777022 | 0.90 | CYP1A2 (0.46) | CYP1A2PDE10AMBNL1ARNPC1 | |
| SCHEMBL30129477 | 0.89 | CYP1A2 (0.45) | CYP1A2PDE10AMBNL1NPC1TGFBR1 | |
| SCHEMBL3789618 | 0.89 | CYP1A2 (0.45) | CYP1A2PDE10AMBNL1NPC1TGFBR1 | |
| SCHEMBL3793053 | 0.89 | CYP1A2 (0.44) | CYP1A2PDE10AMBNL1ARNPC1 | |
| SCHEMBL3785988 | 0.86 | CYP1A2 (0.45) | CYP1A2PDE10AMBNL1NPC1TGFBR1 | |
| SCHEMBL3788033 | 0.86 | CYP1A2 (0.46) | CYP1A2PDE10AARNPC1MAOA | |
| SCHEMBL8776954 | 0.85 | CYP1A2 (0.48) | CYP1A2PDE10ANPC1SMN1; SMN2 | |
| SCHEMBL8776777 | 0.84 | MBNL1 (0.41) | CYP1A2MBNL1ARNPC1 | |
| SCHEMBL8776938 | 0.84 | PDE10A (0.51) | CYP1A2PDE10ANPC1PDGFRBKDR | |
| SCHEMBL8776955 | 0.84 | CYP1A2 (0.42) | CYP1A2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012069652-A2 | FUNGICIDE MIXTURES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-05-31 | — | — | WO | disclosed |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010136475-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | NAT1, NQO2, NOX1 | CYP1A2 18/4885PDE10A 1335/4885MBNL1 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.